MK0826, /Duration of Treatment : 8 Weeks + Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 Weeks
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Complicated Intra-Abdominal Infections
Conditions
Complicated Intra-Abdominal Infections
Trial Timeline
Sep 1, 2001 → May 1, 2004
NCT ID
NCT00389987About MK0826, /Duration of Treatment : 8 Weeks + Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 Weeks
MK0826, /Duration of Treatment : 8 Weeks + Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 Weeks is a phase 3 stage product being developed by Merck for Complicated Intra-Abdominal Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT00389987. Target conditions include Complicated Intra-Abdominal Infections.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00389987 | Phase 3 | Completed |
Competing Products
20 competing products in Complicated Intra-Abdominal Infections